CompletedNot Applicable

Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery

Czechia100 participantsStarted 2016-05-01

Plain-language summary

The radio-guided technique offers both help with in-vivo identification and ex-vivo confirmation of parathyroid adenoma. In-vivo accuracy is most important but its results are not satisfactory. The aim of this study was to evaluate if there is a beneficial effect of individualized timing of surgery using preoperative multi-phase 99mTc-MIBI single-photon emission computed tomography (SPECT)/CT on in-vivo characteristics of minimally invasive radio-guided parathyroidectomy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients * No history of thyroid or parathyroid surgery * Diagnosis of primary hyperparathyroidism * Indication for 99mTc-MIBI SPECT/CT examination Exclusion Criteria: * Minor patients * Negative SPECT/CT findings * Patients refusing surgery * Previous combined surgery on the thyroid gland * Patients in high risk of general anesthesia * Patients who do not undergo surgery in the recommended time span

What they're measuring

Success of surgery (%)

Timeframe: 3 months

In-vivo sensitivity (%)

Timeframe: 3 months

In-vivo specificity (%)

Timeframe: 3 months

In-vivo accuracy (%)

Timeframe: 3 months

Ex-vivo sensitivity (%)

Timeframe: 3 months

Ex-vivo specificity (%)

Timeframe: 3 months

Ex-vivo accuracy (%)

Timeframe: 3 months

Trial details

NCT IDNCT04344886

SponsorUniversity Hospital Ostrava

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-30

View on ClinicalTrials.gov More Primary Hyperparathyroidism trials